Résumé
Le développement des médicaments psychotropes comme celui des autres classes de médicaments a subi un coup d’arrêt depuis une dizaine d’années pour plusieurs raisons qui ne sont souvent pas connues des psychiatres.
Preview
Unable to display preview. Download preview PDF.
References
Becker RE, Greig NH (2010) Lost in translation: neuropsychiatric drug development. Sci Transl Med 2(61): 61rv6
Monod J, Wyman J, Changeux JP (1965) On the nature of allosteric transitions: a plausible model. J Mol Biol 12: 88–118
Kar G, Keskin O, Gursoy A, Nussinov R (2010) Allostery and population shift in drug discovery. Curr Opin Pharmacol 10: 715–22
Burford NT, Watson J, Bertekap R, Alt A (2011) Strategies for the identification of allosteric modulators of G-protein-coupled receptors. Biochem Pharmacol 81: 691–702
De Lean A, Stadel J, Lefkowitz J (1980) A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled beta-adrenergic receptor. J Biol Chem 255: 7108–17
Leff P (1995) The two-state model of receptor activation. Trends Pharmacol Sci 16: 89–97
Kenakin T (1995) Agonist receptor efficacy II; agonist trafficking of receptor signals. Trends Pharmacol Sci 16: 232–8
Salahpour A, Angers S, Bouvier M (2000) Functional significance of Oligomerization of G-protein-coupled receptors. Trends in Endocrinology and metabolism 11: 163–8
Massot O, Rousselle JC, Fillion MP, et al. ( 1999) 5-Hydroxytryptaminemoduline, a new endogenous cerebral peptide, controls the serotonergic activity its specific interaction with 5-HT1B/D receptors. Mol Pharmacol 50: 752–62
Clénet F, Hascoët M, Fillion G, et al. (2005) Role of GABA-ergic and serotonergic systems in the anxiolytic-like mechanism of action of a 5-HT-moduline antagonist in the mouse elevated plus maze. Behav Brain Res 158: 339–48
Hedlund P, Carson M, Sutcliffe G, Thomas E (1999) Allosteric regulation of the binding properties of 5-Hydroxytryptamine7 receptor. Biochem Pharmacol 58: 1807–13
Grazzini E, Guillon G, Mouillac B, Zingg HH (1998) Inhibition of oxytocin receptor function by direct binding of progesterone. Nature 392: 509–12
Canals M, Sexton PM, Christopoulos A (2011) Allostery in GPCRs: ‘MWC’ revisited. Trends Biochem Sci 36: 663–72
Nussinov R, Tsai CJ (2013) Allostery in disease and in drug discovery. Cell 153: 293–305
Thathiah A, Horré K, Snellinx A, et al. (2013)-arrestin 2 regulates A generation and — secretase activity in Alzheimer’s disease. Nature Medicine 19: 43–9
Jiang T, Yu JT, Tan MS, et al. (2013)-Arrestins as Potential Therapeutic Targets for Alzheimer’s Disease. Mol Neurobiol [Epub ahead of print]
Heikkinen T, Lehtimäki K, Vartiainen N, et al. (2012) Characterization of neurophysiological and behavioral changes, MRI brain volumetry and 1H MRS in zQ175 knock-in mouse model of Huntington’s disease. PLoS One 7(12): e50717
Kehler J (2013) Phosphodiesterase 10A inhibitors: a 2009–2012 patent update. Expert Opin Ther Pat 23: 31–45
Raheem IT, Breslin MJ, Fandozzi C, et al. (2012) Discovery of tetrahydropyridopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia. Bioorg Med Chem Lett 22: 5903–8
Hasan A, Mitchell A, Schneider A, et al. (2013) Epigenetic dysregulation in schizophrenia: molecular and clinical aspects of histone deacetylase inhibitors. Eur Arch Psychiatry Clin Neurosci 263: 273–84
Day JJ, Sweatt JD (2012) Epigenetic treatments for cognitive impairments. Neuropsychopharmacology 37: 247–60
Kurita M, Holloway T, García-Bea A, et al. (2012) HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity. Nat Neurosci 15: 1245–54
Abbott BD (2009) Review of the expression of peroxisome proliferator activated receptors alpha (PPAR alpha), beta (PPAR beta), and gamma (PPAR gamma) in rodent and human development. Reprod Toxicol 27: 246–57
Bordet R, Ouk T, Petrault O, et al. (2006) PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases. Biochem Soc Trans 34(Pt6): 1341–6
Moraes LA, Piqueras L, Bishop-Bailey D (2006) Peroxisome proliferatoractivated receptors and inflammation. Pharmacol Ther 110: 371–85
Cimini A, Benedetti E, Cristiano L, et al. (2005) Expression of peroxisome proliferator-activated receptors (PPARs) and retinoic acid receptors (RXRs) in rat cortical neurons. Neuroscience 130: 325–37
Le Foll B, Di Ciano P, Goldberg SR, Ciccocioppo R (2013) Peroxisome Proliferator Activated Receptors (PPAR) Agonists As Promising New Medications For Drug Addiction. Curr Drug Targets 14: 768–76
Salvador-Carulla L, Mezzich JE (2012) Person-centred medicine and mental health. Epidemiol Psychiatr Sci 21: 31–7
Bourin M (1997) Animal models of anxiety: are they suitable for predicting drug action in humans? Pol J Pharmacol. 49: 79–84
Yonutas HM, Sullivan PG (2013) Mechanism of Action of PPAR Agonists in CNS Injury. Curr Drug Targets 14(7): 733–42
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2014 Springer-Verlag France, Paris
About this chapter
Cite this chapter
Bourin, M. (2014). Psychopharmacologie : quels seront les médicaments psychotropes de demain ?. In: Apport des neurosciences à la psychiatrie clinique. Springer, Paris. https://doi.org/10.1007/978-2-8178-0505-4_10
Download citation
DOI: https://doi.org/10.1007/978-2-8178-0505-4_10
Publisher Name: Springer, Paris
Print ISBN: 978-2-8178-0504-7
Online ISBN: 978-2-8178-0505-4
eBook Packages: MedicineMedicine (R0)